February 6, 2017
Leaders of Holden Comprehensive Cancer Center at The University of Iowa announced today that they have joined The Oncology Research Information Exchange Network® (ORIEN), a national initiative among leading cancer centers that promotes collaboration to drive research, development and discovery of treatments and cures for cancer.
ORIEN represents an unprecedented approach to fighting cancer, designed to accelerate the discovery and development of novel therapies for millions of patients. This cancer research collaboration partners 15 U.S. cancer centers with M2Gen, a leading health informatics company based in Tampa, Florida. ORIEN is a first-of-its-kind effort, managing the coordination of data from more than 160,000 patients who have consented to the Total Cancer Care® protocol nationwide. Patients being treated ORIEN member cancer centers consent to share their clinical and molecular data through participation in the Total Cancer Care® (TCC) Protocol. ORIEN members agree to share data with each other in support of collaborations to help uncover important trends that will improve the diagnosis and treatment of an individual’s cancer.
“We are pleased to welcome Holden Comprehensive Cancer Center at The University of Iowa as the newest member of ORIEN,” said William Dalton, PhD, MD, founder and CEO of M2Gen. “ORIEN is a remarkable example of how the spirit of collaboration can inspire new research discoveries to help cancer patients, and we look forward to the next chapter in our shared mission to transform cancer care.”
“The University of Iowa and Holden Comprehensive Cancer Center have a strong history of collaboration, including with the other cancer centers participating in ORIEN,” said George Weiner, MD, director, Holden Comprehensive Cancer Center. “By working together we expect to accelerate our ability to discover and develop new ways to select the best treatment for individual patients and improve outcomes for patients receiving cancer treatment.”
Founded in 2014, ORIEN welcomes the Holden Comprehensive Cancer Center as its 15th member.
About Holden Comprehensive Cancer Center at The University of Iowa
Holden Cancer Center is Iowa's only National Cancer Institute (NCI)-designated comprehensive cancer center and has held that designation since 2000. The NCI designation recognizes the cancer center, and its research scientists, physicians and other health care professionals, for their roles in advancing cancer research that advances our ability to prevent, detect and treat our patients with cancer. NCI-designated comprehensive cancer centers are recognized for their scientific leadership, depth and breadth of research in basic, clinical and population science and impact on their communities.
Oncology Research Information Exchange Network® (ORIEN) is a national research partnership among 14 leading U.S. cancer centers that have joined together in an unprecedented collaboration to study, treat and ultimately cure cancer. Founded in 2014 by Moffitt Cancer Center in Tampa and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, ORIEN is based on a model of cooperation, coordination, and efficiency in cancer research. This first-of-its-kind effort has led to the construction of the world’s largest cancer database, with more than 150,000 patients committing to lifetime study through ORIEN’s Total Cancer Care® (TCC) Protocol. Through this specialized, innovative approach to personalized medicine, researchers can better understand the disease and work in concert towards new developments and discovery in cancer care. Visit their website for more information, or view a full list of ORIEN members.
M2Gen® is a health informatics solutions company focused on accelerating the discovery and development of personalized medicines. M2Gen partners with the nation’s leading cancer centers through ORIEN to create a large, cancer-focused data warehouse linking clinical and molecular data. Using this information, M2Gen helps biopharmaceutical companies address the greatest challenges in oncology drug development. For more information, visit their website.